UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549

SCHEDULE 13G

Under the Securities Exchange Act of 1934 (Amendment No.)*

89bio, Inc.

(Name of Issuer)

Common Stock, par value \$0.001 per share

(Title of Class of Securities)

282559103

(CUSIP Number)

June 29, 2022

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

o Rule 13d-1(b)

⊠ Rule 13d-1(c)

o Rule 13d-1(d)

*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

CUSIP No. 282559103 SCHEDULE 130	Page 2 of 9 Pages
----------------------------------	-------------------

1	NAME OF REPORTING PERSONS				
	Deep Track Capit	Deep Track Capital, LP			
2		ECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP			
2	(a) o (b) x				
	SEC USE ONLY				
3					
	CITIZENSHIP OR PLACE OF ORGANIZATION				
4					
	Delaware	1	COLE MOTING DOWER		
		5	SOLE VOTING POWER		
NI	UMBER OF		0		
	SHARES	6	SHARED VOTING POWER		
	BENEFICIALLY OWNED BY		4,331,499		
	EACH	7	SOLE DISPOSITIVE POWER		
	REPORTING PERSON		0		
	WITH	8	SHARED DISPOSITIVE POWER		
			4,331,499		
	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON				
9 4,331,499*					
		CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES 0			
10	(v) 2.1.2.2.2.2.2.2.2.2.2.2.2.2.2.2.2.2.2.2				
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)					
11					
	9.99%				
12	TYPE OF REPOR	RTING PE	ERSON		
1	IA, OO				

^{*} Includes pre-funded warrants and investment warrants eligible for conversion to common shares

CUSIP No. 282559103 SCHEDULE 13G Page 3 of	9 Pages
--	---------

	NAME OF BERO	DTDIC D	EDGONG		
1	NAME OF REPORTING PERSONS				
1	Deep Track Biotechnology Master Fund, Ltd.				
		CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP			
2	(a) o				
	(b) x				
3	SEC USE ONLY	SEC USE ONLY			
3					
4	CITIZENSHIP OR PLACE OF ORGANIZATION				
4	Cayman Islands	Islands			
			SOLE VOTING POWER		
		5			
NU	NUMBER OF		0		
	SHARES	6	SHARED VOTING POWER		
	BENEFICIALLY OWNED BY EACH		4,331,499		
			SOLE DISPOSITIVE POWER		
	PORTING PERSON	7	0		
	WITH	8	SHARED DISPOSITIVE POWER		
			4,331,499		
9	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON				
9	4,331,499*				
	CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES 0				
10					
	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)				
11					
	9.99%				
12	TYPE OF REPORTING PERSON				
12	co				

^{*} Includes pre-funded warrants and investment warrants eligible for conversion to common shares

CUSIP No. 282559103 SCHEDULE 13G Page 4 of 9 Pa	CUSIP No. 282559103	Page 4 of 9 Pag
---	---------------------	-----------------

	NAME OF PERO	nmn ic n	ED GOLVA		
1	NAME OF REPORTING PERSONS				
	David Kroin	David Kroin			
2		CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP			
2	(a) o (b) x				
	SEC USE ONLY				
3	3				
	CITIZENSHIP OR PLACE OF ORGANIZATION				
4	United States				
	Officed States		SOLE VOTING POWER		
		5			
NU	JMBER OF		0		
	SHARES BENEFICIALLY OWNED BY		SHARED VOTING POWER		
			4,331,499		
DE	EACH	7	SOLE DISPOSITIVE POWER		
	REPORTING PERSON		0		
	WITH	8	SHARED DISPOSITIVE POWER		
			4,331,499		
	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON				
9	4,331,499*				
	CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES o				
10					
	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)				
11	9.99%				
	TYPE OF REPOR	RTING PE	RSON		
12	IN, HC	IN, HC			

^{*} Includes pre-funded warrants and investment warrants eligible for conversion to common shares

CUSI	P No. 282559103	SCHEDULE 13G	Page 5 of 9 Pages		
Item 1.	(a) Name of Issuer				
	89bio, Inc.				
Item 1.	(b) Address of Issuer's Principal Exc	ecutive Offices			
	142 Sansome Street, Second Floor				
	San Francisco, CA 94104				
Item 2.	(a) Names of Persons Filing:				
	(i) Deep Track Capital, LP (ii) Deep Track Biotechnology Mas (iii) David Kroin	ter Fund, Ltd.			
Item 2.	(b) Address of Principal Business O	ffice:			
		Greenwich, CT 06830 190 Elgin Ave, George Town, KY1-9001, Cayman Islands 0 Greenwich Ave, 3rd Floor, Greenwich, CT 06830			
Item 2.	(c) Citizenship:				
	(i) Delaware(ii) Cayman Islands(iii) United States				
Item 2.	(d) Title of Class of Securities				
	Common Stock, par value \$0.001 p	er share (the "Common Stock")			
Item 2.	(e) CUSIP No.:				
	282559103				
CUSI	P No. 282559103	SCHEDULE 13G	Page 6 of 9 Pages		
		§§240.13d-1(b) or 240.13d-2(b) or (c), check whether the p	person filing is a:		
()	· ·	section 15 of the Act (15 U.S.C. 78o);			
(b)					
(c)	* *	section 3(a)(19) of the Act (15 U.S.C. 78c);	2.0.00-0).		
(d)		nder section 8 of the Investment Company Act of 1940 (15 U.S	s.c. ₈₀₄₋₈₎ ,		
(e) (f)		wment fund in accordance with §240.13d-1(b)(1)(ii)(F);			
	 (g) □ A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G); (h) □ A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813); 				
(i)					
(i)	(i) □ A non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J);				
(k)	☐ A group, in accordance with §240	.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accord	dance with §240.13d-1(b)(1)(ii)(J), please		
Not App	plicable				
CUSI	P No. 282559103	SCHEDULE 13G	Page 7 of 9 Pages		
		•			

Information with respect to the Reporting Persons' ownership of the Common Stock as of July 6, 2022, is incorporated by reference to items (5) - (9) and (11) of the cover page of the respective Reporting Person.

The amount beneficially owned by each Reporting Person is determined based on 43,358,349 Common Stock outstanding.

Item 5. Ownership of Five Percent or Less of a Class

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [].

Item 6. Ownership of More Than Five Percent on Behalf of Another Person

Not Applicable.

Item 7. Identification and Classification of the Subsidiary which Acquired the Security Being Reported on by the Parent Holding Company or Control Person

Deep Track Capital, LP is the relevant entity for which David Kroin may be considered a control person.

Item 8. Identification and Classification of Members of the Group

Not Applicable.

Item 9. Notice of Dissolution of Group

Not Applicable.

Item 10. Certification

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Dated: July 6, 2022

Deep Track Capital, LP

By: /s/ David Kroin

David Kroin, Managing Member of the General Partner of the

Investment Adviser

Deep Track Biotechnology Master Fund, Ltd.

By: /s/ David Kroin

David Kroin, Director

David Kroin

By: /s/ David Kroin

David Kroin

Exhibit I

JOINT FILING STATEMENT

PURSUANT TO RULE 13d-1(k)

The undersigned acknowledge and agree that the foregoing statement on Schedule 13G, is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G, shall be filed on behalf of each of the undersigned without the necessity of filing additional joint acquisition statements. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning him or it contained therein, but shall not be responsible for the completeness and accuracy of the information concerning the others, except to the extent that he or it knows or has reason to believe that such information is inaccurate.

Dated: July 6, 2022

Deep Track Capital, LP

By: /s/ David Kroin

David Kroin, Managing Member of the General Partner of the Investment Adviser

Deep Track Biotechnology Master Fund, Ltd.

By: /s/ David Kroin

David Kroin, Director

David Kroin

By: /s/ David Kroin

David Kroin